Managing patients with vascular disease and depression

Journal of Clinical Psychiatry

Volumn 67, Issue 10, 2006, Pages 1633-1644

  Roose, Steven P ^a   Glassman, Alexander ^a   Mathew, Sanjay J ^b   Musselman, Dominique ^c   Nelson, J Craig ^d   Steffens, David C ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPERTENSIVE AGENT; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY DISORDER; BIPOLAR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DYSTHYMIA; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOTHERAPY; RISK FACTOR; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; STROKE; THROMBOSIS; VASCULAR DISEASE;

EID: 33751205610     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1021     Document Type: Conference Paper

References (92)

1. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge. Mass: Harvard University Press; 1996
2. US Dept of Health and Human Services. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ nchs/data/hus/hus.05.pdf#executive summary. Accessed Aug 22, 2006
3. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709
4. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1-48
5. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078
6. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-592
7. Cohen-Cole SA, Brown FW, McDaniel JS. Diagnostic assessment of depression in the medically ill. In: Stoudemire A, Fogel B, eds. Principles of Medical Psychiatry. Second Edition ed. New York, NY: Oxford University Press; 1993:53-70
8. Wassertheil-Smoller S, Applegate WB, Berge W, et al, for the SHEP Cooperative Research Group (Systolic Hypertension in the Elderly Program). Change in depression as a precursor of cardiovascular events. Arch Intern Med 1996;156: 553-561
9. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? a systematic quantitative review. Psychosom Med 2003;65:201-210
10. Frasure-Smith N, Lesperance R, Talajic M. Depression following myocardial infarction: impact on 6-months survival. JAMA 1993;270:1819-1825
11. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66: 814-822
12. Lesperance F, Erasure-Smith N, Talajic M, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002;105:1049-1053
13. Carnethon MR, Kinder LS, Fair JM, et al. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. Am J Epidemiol 2003;158:416-423
14. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54: 317-329
15. Winokur A, Maislin G, Phillips JL, et al. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988;145:325-330
16. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257
17. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-1159
18. Ford DE, Erlinger DP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004;164:1010-1014
19. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-140
20. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-658
21. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 2005;19:113-122
22. National Diabetes Information Clearing-house (NDIC). National Diabetes Statistics. NIH Publication No 06-3892. November 2005. Available at http:// diabetes.niddk.nih.gov/dm/pubs/statistics/ index.htm#7. Accessed July 28, 2006
23. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002;15 (suppl 2):737-744
24. Brown ES, Varghese FP, McEwan BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004;55:1-9
25. Eaton WW, Armenian H, Gallo J, et al. Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care 1996;19:1097-1102
26. Kawakami N, Takatsuka N, Shimizu H, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999;22:1071-1076
27. Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004;27:2856-2862
28. Boden G, Hoeldtke RD. Nerves, fat, and insulin resistance. N Engl J Med 2003;349: 1966-1967
29. Klein JP, Waxman SG. The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. Lancet Neurol 2003;2:548-554
30. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101-2107
31. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-630
32. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-942
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497
34. Goodwin RD, Weisberg SP. Childhood abuse and diabetes in the community [letter]. Diabetes Care 2002;24:801-802
35. Goodwin RD, Stein MB. Association between childhood trauma and physical disorders among adults in the United States. Psychol Med 2004;34:509-520
36. Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006;63:521-529
37. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004;61:1042-1049
38. McIntyre RS, Soczynska J, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006;5:157-168
39. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995;56: 128-136
40. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59:241-240
41. Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapine-induced weight gain [letter]. Am J Psychiatry 2003;160:797
42. Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997; 21:97-102
43. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
44. Despres JP, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134
45. Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med 2000;247:629-639
46. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocardial infarction. Arch Gen Psychiatry 2003;60:627-636
47. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-3116
48. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002;159:191-200
49. O'Connor CM, Glassman AH, Harrison DJ. Pharmacoeconornic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005;66: 346-352
50. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-798
51. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2006 update. Circulation 2006;113: e85-e151. Available at http:// www.circ.ahajournals.org/cgi/content/ full/ 113/6/e85. Accessed Aug 16, 2006
52. Burvill PW, Johnson GA, Jamrozik KD, et al. Prevalence of depression after stroke: the Perth Community Stroke Study. Br J Psychiatry 1995;166:320-327
53. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002;52:253-264
54. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke 2005;36: 2296-2301
55. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993;24:976-982
56. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke 1987;18: 837-843
57. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25: 1099-1104
58. Gillen R, Tennen H, McKee TE, et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001;82:1645-1649
59. Parikh RM, Robinson RG, Lipsey JR, et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol 1990;47: 785-789
60. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001;32:696-701
61. Folstein MR, Maiberger R, McHugh PR. Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 1977;40:1018-1020
62. Robinson RG, Szetela B. Mood change following left hemispheric brain injury. Ann Neurol 1981;9:447-453
63. Robinson RG, Kubos KL, Starr LB, et al. Mood disorders in stroke patients: importance of location of lesion. Brain 1984;107, pt 1:81-93
64. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet 2000;356: 122-126
65. Herrmann M, Wallesch CW. Depressive changes in stroke patients. Disabil Rehabil 1993;15:55-66
66. House A. Depression associated with stroke. J Neuropsychiatry Clin Neurosci 1996;8:453-457
67. Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2004:CD003437
68. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-359
69. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250:347-351
70. Rampello L, Battaglia G, Raffaele R, et al. Is it safe to use antidepressants after a stroke? Expert Opin Drug Saf 2005;4: 885-897
71. Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998;28: 1015-1026
72. Steffens DC, MacFall JR, Payne ME, et al. Grey-matter lesions and dementia [letter]. Lancet 2000;19:1686-1687
73. Steffens DC, Bosworth HB, Provenzale JM, et al. Subcortical white matter lesions and functional impairment in geriatric depression. Depress Anxiety 2002;15:23-28
74. Levy RM, Steffens DC, McQuoid DR, et al. MRI lesion seventy and mortality in geriatric depression. Am J Geriatr Psychiatry 2003;11:678-682
75. Steffens DC, Krishnan KR. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psychiatry 1998;43:705-712
76. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
77. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 1988;145: 976-981
78. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(suppl 20):9-15
79. Koike AK, Unützer J, Wells KB. Improving the care for depression in patients with comorbid medical disease. Am J Psychiatry 2002;159:1738-1745
80. Simon GE, Von Korff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335
81. Kirmayer LJ, Robbins JM, Dworkind M. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741
82. Clark DC, von Ammon CS, Gibbons RD. The core symptoms of depression in medical and psychiatric patients. J Nerv Ment Dis 1983;171:705-713
83. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 2003;160: 2122-2127
84. Iosifescu DV, Nierenberg AA, Alpert JE. et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics 2004;45:419-425
85. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003;17:517-538
86. Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002;288:2836-2845
87. Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004; 56:46-53
88. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
89. Maines TY, Lavie CJ, Milani RV, et al. Effects of cardiac rehabilitation and exercise programs on exercise capacity, coronary risk factors, behavior, and quality of life in patients with coronary artery disease. South Med J 1997;90:43-49
90. Gaede P, Beck M, Vedel P, et al. Limited impact of lifestyle education in patients with type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. Diabet Med 2001;18: 104-108
91. Keers JC, Bouma J, Links TP, et al. One-year follow-up effects of diabetes rehabilitation for patients with prolonged self-management difficulties. Patient Educ Couns 2006;60:16-23
92. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996;156:745-752